cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.7910/dvn/4ila3
title: Senate Unpassed Legislation 1855, Docket 18373, SC1/series 231, Petition of William Babbitt

description: &lt;p&gt;Petition subject: For the removal of Edward Greeley Loring &lt;/p&gt; &lt;p&gt;Original: &lt;a href="http://nrs.harvard.edu/urn-3:FHCL:11858551"&gt;http://nrs.harvard.edu/urn-3:FHCL:11858551&lt;/a&gt; &lt;/p&gt; &lt;p&gt;Date of creation: (unknown) &lt;/p&gt; &lt;p&gt;Petition location: Savoy &lt;/p&gt; &lt;p&gt;Legislator, committee, or address that the petition was sent to: Harmon Snow, Savoy; committee on federal relations &lt;/p&gt; &lt;p&gt;Selected signatures:&lt;ol&gt;&lt;li&gt;William Babbitt&lt;/li&gt;&lt;li&gt;Joseph B. Ingraham&lt;/li&gt;&lt;li&gt;Ebenezer Codding&lt;/li&gt;&lt;/ol&gt; &lt;/p&gt; &lt;p&gt;Actions taken on dates: 1855-03-10,1855-03-12 &lt;/p&gt; &lt;p&gt;Legislative action: Received in the House on March 10, 1855 and referred to the committee on federal relations and sent for concurrence and received in the Senate on March 12, 1855 and concurred &lt;/p&gt; &lt;p&gt;Total signatures: 31 &lt;/p&gt; &lt;p&gt;Legislative action summary: Received, referred, sent, received, concurred &lt;/p&gt; &lt;p&gt;Legal voter signatures (males not identified as non-legal): 31 &lt;/p&gt; &lt;p&gt;Female only signatures: No &lt;/p&gt; &lt;p&gt;Identifications of signatories: inhabitants &lt;/p&gt; &lt;p&gt;Prayer format was &lt;a href="http://en.wikipedia.org/wiki/Printing"&gt;printed&lt;/a&gt; vs. &lt;a href="http://en.wikipedia.org/wiki/Manuscript"&gt;manuscript&lt;/a&gt;: Manuscript &lt;/p&gt; &lt;p&gt;Additional non-petition or unrelated documents available at archive: no additional documents &lt;/p&gt; &lt;p&gt;Location of the petition at the Massachusetts Archives of the Commonwealth: Senate Unpassed 1855, Docket 18373 &lt;/p&gt; &lt;p&gt;Acknowledgements: Supported by the National Endowment for the Humanities (PW-5105612), Massachusetts Archives of the Commonwealth, Radcliffe Institute for Advanced Study at Harvard University, Center for American Political Studies at Harvard University, Institutional Development Initiative at Harvard University, and Harvard University Library.&lt;/p&gt;
DOI: 10.6084/m9.figshare.30333935
title: Biological activity of pumpkin pulp extracts: cytoprotection, anti-inflammatory effects, and photoprotection in human skin cells

description: Pumpkin extracts are rich in vitamins and bioactive compounds, offering antioxidative, anti-inflammatory, and wound-healing properties, making them valuable in dermatology and cosmetics, however pumpkin pulp extracts have not been evaluated before for their cutaneous biological activities. This study evaluated the biological activity of methanolic pumpkin pulp extracts from six Serbian accessions of <i>Cucurbita (C.) maxima</i> and <i>C. moschata</i> on normal keratinocytes (HaCaT) and melanoma (FemX) cells. The extracts showed no cytotoxicity to normal cells up to 1000 μg/mL and exhibited concentration-dependent cytotoxicity to melanoma cells (determined by MTT assay). They also demonstrated antioxidative effects against H<sub>2</sub>O<sub>2</sub>-induced oxidative stress in H<sub>2</sub>DCFDA assay, and reduced tumor necrosis factor -α/interferon-gamma-γ-induced expression of pro-inflammatory cytokine interleukine-1β in HaCaT cells, as shown in the cell-based ELISA assay. Sun protection factor (SPF) calculations for all six accessions confirmed the photoprotective potential of the extracts, with noticeable differences in SPF values between species and varieties. The highest SPF value was observed in the <i>C. moschata</i> variety. Significant variations in biological activities among the examined accessions were noted, with <i>C. maxima</i> extracts showing pronounced antioxidant and antiinflammatory properties while <i>C. moschata</i> extract showed the highest SPF values. These findings represent the first report on the skin-beneficial effects of pumpkin pulp extracts, identifying them as sustainable sources of safe, bioactive compounds with antioxidant, anti-inflammatory, and photoprotective properties for dermatological or cosmetic applications.
DOI: 10.6084/m9.figshare.30333935.v2
title: Biological activity of pumpkin pulp extracts: cytoprotection, anti-inflammatory effects, and photoprotection in human skin cells

description: Pumpkin extracts are rich in vitamins and bioactive compounds, offering antioxidative, anti-inflammatory, and wound-healing properties, making them valuable in dermatology and cosmetics, however pumpkin pulp extracts have not been evaluated before for their cutaneous biological activities. This study evaluated the biological activity of methanolic pumpkin pulp extracts from six Serbian accessions of <i>Cucurbita (C.) maxima</i> and <i>C. moschata</i> on normal keratinocytes (HaCaT) and melanoma (FemX) cells. The extracts showed no cytotoxicity to normal cells up to 1000 μg/mL and exhibited concentration-dependent cytotoxicity to melanoma cells (determined by MTT assay). They also demonstrated antioxidative effects against H<sub>2</sub>O<sub>2</sub>-induced oxidative stress in H<sub>2</sub>DCFDA assay, and reduced tumor necrosis factor -α/interferon-gamma-γ-induced expression of pro-inflammatory cytokine interleukine-1β in HaCaT cells, as shown in the cell-based ELISA assay. Sun protection factor (SPF) calculations for all six accessions confirmed the photoprotective potential of the extracts, with noticeable differences in SPF values between species and varieties. The highest SPF value was observed in the <i>C. moschata</i> variety. Significant variations in biological activities among the examined accessions were noted, with <i>C. maxima</i> extracts showing pronounced antioxidant and antiinflammatory properties while <i>C. moschata</i> extract showed the highest SPF values. These findings represent the first report on the skin-beneficial effects of pumpkin pulp extracts, identifying them as sustainable sources of safe, bioactive compounds with antioxidant, anti-inflammatory, and photoprotective properties for dermatological or cosmetic applications.
DOI: 10.15468/dl.3f7pxw
title: Occurrence Download

description: A dataset containing 1916 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Plantae",
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "Country is Germany",
 "DecimalLongitude is greater than or equal to 6.81785104034678",
 "DecimalLongitude is less than 6.82091059353118",
 "DecimalLatitude is greater than or equal to 47.27011",
 "DecimalLatitude is less than or equal to 55.05864"
 ]
}

 The dataset includes 1916 records from 12 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0045789-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30304309
title: Predictors of response to omalizumab in chronic spontaneous urticaria: a retrospective cohort study

description: Although omalizumab is a highly effective treatment against chronic spontaneous urticaria (CSU), the treatment duration for response varies among patients. Thus, determining easy-to-access predictive biomarkers of omalizumab response is essential. This study aimed to investigate the value of baseline hematological and inflammatory parameters and patient-specific features as predictive markers of response to standard-dose omalizumab. This single-center retrospective cohort study was conducted on 242 patients with CSU treated with omalizumab 300 mg every 4 weeks for at least 6 months between 2014 and 2025. The demographics, clinical features, treatment responses, and baseline laboratory tests were assessed. Response to omalizumab was evaluated based on the weekly Urticaria Activity Score (UAS7). Patients were categorized as early responder (ER, within 3 months), late responder (LR, after 3 months), and nonresponder (NR). Of patients, 180 (74.4%) were classified as ER, 28 (11.6%) as LR, and 34 (14%) as NR. ERs had higher white blood cell (WBC) and lymphocyte counts (<i>p</i> = 0.047 and <i>p</i> = 0.005, respectively) and lower mean platelet volume (MPV)/lymphocyte ratio (MPVLR) (<i>p</i> = 0.008). LRs had higher mean corpuscular hemoglobin concentration (MCHC) and platelet/lymphocyte ratio (PLR) (<i>p</i> = 0.023 and <i>p</i> = 0.014, respectively) and lower MPV levels (<i>p</i> = 0.043). The platelet distribution width (PDW) was higher in the NRs (<i>p</i> = 0.011). Red cell distribution width-coefficient of variation (RDW-CV) [odds ratio (OR): 0.793, 95% confidence interval (CI): 0.641–0.980, <i>p</i> = 0.032], WBC count (OR: 1.418, 95% CI: 1.093–1.840, <i>p</i> = 0.009), and PDW (OR: 0.813, 95% CI: 0.693–0.954, <i>p</i> = 0.011) were found to be the independent predictors of responders. The lymphocyte count (OR: 1.713, 95% CI: 1.122–2.613, <i>p</i> = 0.013) and MPVLR (OR: 0.427, 95% CI: 0.218–0.837, <i>p</i> = 0.013) were independent predictors of ER, whereas MCHC (OR: 2.368, 95% CI: 1.522–3.686, <i>p</i> &lt; 0.001) and PLR (OR: 1.010, 95% CI: 1.003–1.017, <i>p</i> = 0.003) were independent predictors of LR. The receiver operating characteristic curve analysis results showed that the predictive strengths of RDW-CV, WBC count, PDW, lymphocyte count, MPVLR, MCHC, and PLR were low (the area under the curve values 0.634, 0.620, 0.672, 0.656, 0.621, 0.649, and 0.624, respectively; all <i>p</i> &lt; 0.05), suggesting the limited use of these parameters in clinical practice. The limitations of this study included its single-center, retrospective design, lack of external validation, and reliance solely on UAS7 for assessing disease activity. WBC and lymphocyte counts, RDW-CV, PDW, MPVLR, MCHC, and PLR can be considered when appraising the omalizumab response. However, given their limited predictive strength, these parameters alone may not accurately predict the efficacy of omalizumab.
DOI: 10.6084/m9.figshare.30304309.v1
title: Predictors of response to omalizumab in chronic spontaneous urticaria: a retrospective cohort study

description: Although omalizumab is a highly effective treatment against chronic spontaneous urticaria (CSU), the treatment duration for response varies among patients. Thus, determining easy-to-access predictive biomarkers of omalizumab response is essential. This study aimed to investigate the value of baseline hematological and inflammatory parameters and patient-specific features as predictive markers of response to standard-dose omalizumab. This single-center retrospective cohort study was conducted on 242 patients with CSU treated with omalizumab 300 mg every 4 weeks for at least 6 months between 2014 and 2025. The demographics, clinical features, treatment responses, and baseline laboratory tests were assessed. Response to omalizumab was evaluated based on the weekly Urticaria Activity Score (UAS7). Patients were categorized as early responder (ER, within 3 months), late responder (LR, after 3 months), and nonresponder (NR). Of patients, 180 (74.4%) were classified as ER, 28 (11.6%) as LR, and 34 (14%) as NR. ERs had higher white blood cell (WBC) and lymphocyte counts (<i>p</i> = 0.047 and <i>p</i> = 0.005, respectively) and lower mean platelet volume (MPV)/lymphocyte ratio (MPVLR) (<i>p</i> = 0.008). LRs had higher mean corpuscular hemoglobin concentration (MCHC) and platelet/lymphocyte ratio (PLR) (<i>p</i> = 0.023 and <i>p</i> = 0.014, respectively) and lower MPV levels (<i>p</i> = 0.043). The platelet distribution width (PDW) was higher in the NRs (<i>p</i> = 0.011). Red cell distribution width-coefficient of variation (RDW-CV) [odds ratio (OR): 0.793, 95% confidence interval (CI): 0.641–0.980, <i>p</i> = 0.032], WBC count (OR: 1.418, 95% CI: 1.093–1.840, <i>p</i> = 0.009), and PDW (OR: 0.813, 95% CI: 0.693–0.954, <i>p</i> = 0.011) were found to be the independent predictors of responders. The lymphocyte count (OR: 1.713, 95% CI: 1.122–2.613, <i>p</i> = 0.013) and MPVLR (OR: 0.427, 95% CI: 0.218–0.837, <i>p</i> = 0.013) were independent predictors of ER, whereas MCHC (OR: 2.368, 95% CI: 1.522–3.686, <i>p</i> &lt; 0.001) and PLR (OR: 1.010, 95% CI: 1.003–1.017, <i>p</i> = 0.003) were independent predictors of LR. The receiver operating characteristic curve analysis results showed that the predictive strengths of RDW-CV, WBC count, PDW, lymphocyte count, MPVLR, MCHC, and PLR were low (the area under the curve values 0.634, 0.620, 0.672, 0.656, 0.621, 0.649, and 0.624, respectively; all <i>p</i> &lt; 0.05), suggesting the limited use of these parameters in clinical practice. The limitations of this study included its single-center, retrospective design, lack of external validation, and reliance solely on UAS7 for assessing disease activity. WBC and lymphocyte counts, RDW-CV, PDW, MPVLR, MCHC, and PLR can be considered when appraising the omalizumab response. However, given their limited predictive strength, these parameters alone may not accurately predict the efficacy of omalizumab.
DOI: 10.6084/m9.figshare.30333935.v1
title: Biological activity of pumpkin pulp extracts: cytoprotection, anti-inflammatory effects, and photoprotection in human skin cells

description: Pumpkin extracts are rich in vitamins and bioactive compounds, offering antioxidative, anti-inflammatory, and wound-healing properties, making them valuable in dermatology and cosmetics, however pumpkin pulp extracts have not been evaluated before for their cutaneous biological activities. This study evaluated the biological activity of methanolic pumpkin pulp extracts from six Serbian accessions of <i>Cucurbita (C.) maxima</i> and <i>C. moschata</i> on normal keratinocytes (HaCaT) and melanoma (FemX) cells. The extracts showed no cytotoxicity to normal cells up to 1000 μg/mL and exhibited concentration-dependent cytotoxicity to melanoma cells (determined by MTT assay). They also demonstrated antioxidative effects against H<sub>2</sub>O<sub>2</sub>-induced oxidative stress in H<sub>2</sub>DCFDA assay, and reduced tumor necrosis factor -α/interferon-gamma-γ-induced expression of pro-inflammatory cytokine interleukine-1β in HaCaT cells, as shown in the cell-based ELISA assay. Sun protection factor (SPF) calculations for all six accessions confirmed the photoprotective potential of the extracts, with noticeable differences in SPF values between species and varieties. The highest SPF value was observed in the <i>C. moschata</i> variety. Significant variations in biological activities among the examined accessions were noted, with <i>C. maxima</i> extracts showing pronounced antioxidant and antiinflammatory properties while <i>C. moschata</i> extract showed the highest SPF values. These findings represent the first report on the skin-beneficial effects of pumpkin pulp extracts, identifying them as sustainable sources of safe, bioactive compounds with antioxidant, anti-inflammatory, and photoprotective properties for dermatological or cosmetic applications.
DOI: 10.6084/m9.figshare.30510536
title: Effect of silver nitrate solution on corneal epithelial barrier function in rabbits

description: Some preservatives in eye drops induce corneal epithelial damage. Diquafosol sodium, a dry eye treatment drug released in 2022, contains silver nitrate as a preservative. This study examined the effects of diquafosol sodium ophthalmic solution and silver nitrate solution on the barrier function of corneal epithelial cells in rabbit eyes. The 14 rabbits included in the study were divided into 7 eye drop treatment groups (4 eyes per group): (1) 3% diquafosol (Diquas) without silver nitrate; (2) 3% Diquas LX containing silver nitrate; (3) 3% Diquas LX without silver nitrate; (4) 0.01% silver nitrate; (5) 0.1% silver nitrate; (6) 1% silver nitrate; and (7) saline. Electrical corneal resistance (CR) was measured using a CR-measuring device (CRD) at 30, 60, and 120 minutes after the final instillation, and CR% was calculated. Corneal epithelial damage was evaluated using fluorescein staining 120 minutes after the final instillation.Corneal tissue obtained 120 minutes post-instillation was fixed in 4% paraformaldehyde, permeabilized, and blocked. Zonula occludens-1 protein, which constitutes tight junctions between epithelial cells, was visualized using whole-mount immunohistochemical staining. To examine the expression of ZO-1 in corneal epithelial cells, photographs of the outermost layer of the cornea were taken. CR in the Diquas LX group 1 (containing silver nitrate) reached its peak value (114.2 ± 7.1%) 60 minutes after the final instillation, which was comparable to that in the 0.1% silver nitrate group (117.2 ± 17.6%) and significantly higher than that in the Diquas group 3 (without silver nitrate) (98.8 ± 5.8%; <i>P</i> &lt; 0.05). Zonular occludens-1 protein was localized in a continuous linear pattern at the boundary between epithelial cells in all three Diquas groups. Diquas LX eye drops containing silver nitrate significantly increased CR compared to Diquas eye drops without silver nitrate and improved corneal barrier function. Silver nitrate as a preservative may have contributed to this effect.
DOI: 10.6084/m9.figshare.30510536.v1
title: Effect of silver nitrate solution on corneal epithelial barrier function in rabbits

description: Some preservatives in eye drops induce corneal epithelial damage. Diquafosol sodium, a dry eye treatment drug released in 2022, contains silver nitrate as a preservative. This study examined the effects of diquafosol sodium ophthalmic solution and silver nitrate solution on the barrier function of corneal epithelial cells in rabbit eyes. The 14 rabbits included in the study were divided into 7 eye drop treatment groups (4 eyes per group): (1) 3% diquafosol (Diquas) without silver nitrate; (2) 3% Diquas LX containing silver nitrate; (3) 3% Diquas LX without silver nitrate; (4) 0.01% silver nitrate; (5) 0.1% silver nitrate; (6) 1% silver nitrate; and (7) saline. Electrical corneal resistance (CR) was measured using a CR-measuring device (CRD) at 30, 60, and 120 minutes after the final instillation, and CR% was calculated. Corneal epithelial damage was evaluated using fluorescein staining 120 minutes after the final instillation.Corneal tissue obtained 120 minutes post-instillation was fixed in 4% paraformaldehyde, permeabilized, and blocked. Zonula occludens-1 protein, which constitutes tight junctions between epithelial cells, was visualized using whole-mount immunohistochemical staining. To examine the expression of ZO-1 in corneal epithelial cells, photographs of the outermost layer of the cornea were taken. CR in the Diquas LX group 1 (containing silver nitrate) reached its peak value (114.2 ± 7.1%) 60 minutes after the final instillation, which was comparable to that in the 0.1% silver nitrate group (117.2 ± 17.6%) and significantly higher than that in the Diquas group 3 (without silver nitrate) (98.8 ± 5.8%; <i>P</i> &lt; 0.05). Zonular occludens-1 protein was localized in a continuous linear pattern at the boundary between epithelial cells in all three Diquas groups. Diquas LX eye drops containing silver nitrate significantly increased CR compared to Diquas eye drops without silver nitrate and improved corneal barrier function. Silver nitrate as a preservative may have contributed to this effect.
DOI: 10.6084/m9.figshare.30366133
title: A systematic review of ionizing radiation-induced glaucoma: clinical manifestations, pathogenesis, and current treatment approaches

description: Ionizing radiation-induced glaucoma (IRG) is an uncommon yet vision-threatening complication that presents primarily as neovascular glaucoma (NVG) after high-dose exposure and normal-tension glaucoma (NTG) after low-dose exposure. Despite increasing recognition, its dose–response relationship, mechanisms, and optimal management remain poorly defined. This review evaluates the clinical spectrum, pathogenesis, and therapeutic approaches of IRG to inform future research and practice. A systematic literature search of PubMed/MEDLINE, Embase, Scopus, and the Cochrane Database (1964–2024) was conducted following PRISMA guidelines. Among 7256 screened articles, 37 studies fulfilled the inclusion criteria. NVG typically develops following ocular radiotherapy exceeding 30 Gy, particularly in patients with uveal melanoma, and is characterized by retinal ischemia, neovascularization, and secondary intraocular pressure elevation. NTG arises from chronic low-dose exposure (&lt; 1 Gy), producing optic nerve injury and visual field loss without elevated pressure. Anti-VEGF therapy can temporarily control NVG progression, whereas trabeculectomy, glaucoma drainage devices, and cyclodestructive procedures are variably employed but often limited by postoperative complications and inconsistent outcomes. The lack of consensus-driven protocols and heterogeneity across studies underscore ongoing clinical challenges. IRG represents a dose-dependent entity with distinct phenotypes and mechanisms. Current therapies provide partial benefit but remain unsatisfactory in terms of durability and standardization. Advancing the field will require mechanistic studies to clarify radiation-induced optic neuropathy and vascular injury, alongside well-designed trials to establish preventive strategies and evidence-based treatment algorithms.
DOI: 10.6084/m9.figshare.30366133.v1
title: A systematic review of ionizing radiation-induced glaucoma: clinical manifestations, pathogenesis, and current treatment approaches

description: Ionizing radiation-induced glaucoma (IRG) is an uncommon yet vision-threatening complication that presents primarily as neovascular glaucoma (NVG) after high-dose exposure and normal-tension glaucoma (NTG) after low-dose exposure. Despite increasing recognition, its dose–response relationship, mechanisms, and optimal management remain poorly defined. This review evaluates the clinical spectrum, pathogenesis, and therapeutic approaches of IRG to inform future research and practice. A systematic literature search of PubMed/MEDLINE, Embase, Scopus, and the Cochrane Database (1964–2024) was conducted following PRISMA guidelines. Among 7256 screened articles, 37 studies fulfilled the inclusion criteria. NVG typically develops following ocular radiotherapy exceeding 30 Gy, particularly in patients with uveal melanoma, and is characterized by retinal ischemia, neovascularization, and secondary intraocular pressure elevation. NTG arises from chronic low-dose exposure (&lt; 1 Gy), producing optic nerve injury and visual field loss without elevated pressure. Anti-VEGF therapy can temporarily control NVG progression, whereas trabeculectomy, glaucoma drainage devices, and cyclodestructive procedures are variably employed but often limited by postoperative complications and inconsistent outcomes. The lack of consensus-driven protocols and heterogeneity across studies underscore ongoing clinical challenges. IRG represents a dose-dependent entity with distinct phenotypes and mechanisms. Current therapies provide partial benefit but remain unsatisfactory in terms of durability and standardization. Advancing the field will require mechanistic studies to clarify radiation-induced optic neuropathy and vascular injury, alongside well-designed trials to establish preventive strategies and evidence-based treatment algorithms.
DOI: 10.15468/dl.6vsena
title: Occurrence Download

description: A dataset containing 45 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((-111.7188 28.64913, -111.5688 28.64913, -111.5688 28.79913, -111.7188 28.79913, -111.7188 28.64913))"
 ]
}

 The dataset includes 45 records from 14 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0045790-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.